Sure. So this was a Phase II trial. It was a two stage design and we rolled a total of 16 patients. All patients received the combination of mirvetuximab soravtansine, which is a folate receptor alpha targeting antibody drug conjugate, and pembrolizumab, an immune checkpoint inhibitor. And there’s a lot of pre-clinical data to support that concept of combining ADCs and immune checkpoint blockade, which was the basis for this study...
Sure. So this was a Phase II trial. It was a two stage design and we rolled a total of 16 patients. All patients received the combination of mirvetuximab soravtansine, which is a folate receptor alpha targeting antibody drug conjugate, and pembrolizumab, an immune checkpoint inhibitor. And there’s a lot of pre-clinical data to support that concept of combining ADCs and immune checkpoint blockade, which was the basis for this study. And this was in patients specifically with serious endometrial cancer that are mismatch repair proficient, so wouldn’t be expected to respond well to immunotherapy alone. All patients received the therapy. And I think the notable thing is that the response rate was really favorable for this population of patients with six patients having an objective response, one with a confirmed complete response and then three confirmed and two unconfirmed partial responses.
